Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NT5E | P21589 | 1/20 | 0.58 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.53 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.53 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.53 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | HTR2C | P28335 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17920478 | 0.93 | ADORA1 (0.61) | NT5EADORA2AADORA1ADORA3ADORA2B | |
| SCHEMBL17920514 | 0.90 | NT5E (0.70) | NT5EADORA2AADORA1ADORA3ADORA2B | |
| SCHEMBL17920435 | 0.90 | NT5E (0.70) | NT5EADORA2AADORA1ADORA3ADORA2B | |
| SCHEMBL17213465 | 0.84 | NT5E (0.54) | NT5EADORA2AADORA1ADORA3ADORA2B | |
| SCHEMBL17920513 | 0.83 | NT5E (0.60) | NT5EADORA2AADORA1ADORA3ADORA2B | |
| SCHEMBL17920430 | 0.83 | NT5E (0.60) | NT5EADORA2AADORA1ADORA3ADORA2B | |
| SCHEMBL17920431 | 0.82 | PNP (0.60) | NT5EADORA1ADORA3RXFP1LMNA | |
| SCHEMBL24026356 | 0.82 | PNP (0.60) | NT5EADORA1ADORA3RXFP1LMNA | |
| SCHEMBL20347308 | 0.82 | LMNA (0.52) | NT5EADORA2AADORA1ADORA3ADORA2B | |
| SCHEMBL17920510 | 0.82 | PNP (0.60) | NT5EADORA1ADORA3RXFP1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230002437-A1 | ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOF | ANTENGENE THERAPEUTICS LIMITED (CN) | 2023-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230002437-A1 | ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOF | NT5E, ENTPD5, NT5C2 | NT5E 1/4885ADORA2A 27/4885ADORA1 36/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.